Ahmed Khashaba
Ain Shams University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ahmed Khashaba.
The New England Journal of Medicine | 2017
Justin E. Davies; Sayan Sen; Hakim-Moulay Dehbi; Rasha Al-Lamee; Ricardo Petraco; Sukhjinder Nijjer; Ravinay Bhindi; Sam J. Lehman; D. Walters; James Sapontis; Luc Janssens; Christiaan J. Vrints; Ahmed Khashaba; Mika Laine; Eric Van Belle; Florian Krackhardt; Waldemar Bojara; Olaf Going; Tobias Härle; Ciro Indolfi; Giampaolo Niccoli; Flavo Ribichini; Nobuhiro Tanaka; Hiroyoshi Yokoi; Hiroaki Takashima; Yuetsu Kikuta; Andrejs Erglis; Hugo Vinhas; Pedro Canas Silva; Sérgio B. Baptista
Background Coronary revascularization guided by fractional flow reserve (FFR) is associated with better patient outcomes after the procedure than revascularization guided by angiography alone. It is unknown whether the instantaneous wave‐free ratio (iFR), an alternative measure that does not require the administration of adenosine, will offer benefits similar to those of FFR. Methods We randomly assigned 2492 patients with coronary artery disease, in a 1:1 ratio, to undergo either iFR‐guided or FFR‐guided coronary revascularization. The primary end point was the 1‐year risk of major adverse cardiac events, which were a composite of death from any cause, nonfatal myocardial infarction, or unplanned revascularization. The trial was designed to show the noninferiority of iFR to FFR, with a margin of 3.4 percentage points for the difference in risk. Results At 1 year, the primary end point had occurred in 78 of 1148 patients (6.8%) in the iFR group and in 83 of 1182 patients (7.0%) in the FFR group (difference in risk, ‐0.2 percentage points; 95% confidence interval [CI], ‐2.3 to 1.8; P<0.001 for noninferiority; hazard ratio, 0.95; 95% CI, 0.68 to 1.33; P=0.78). The risk of each component of the primary end point and of death from cardiovascular or noncardiovascular causes did not differ significantly between the groups. The number of patients who had adverse procedural symptoms and clinical signs was significantly lower in the iFR group than in the FFR group (39 patients [3.1%] vs. 385 patients [30.8%], P<0.001), and the median procedural time was significantly shorter (40.5 minutes vs. 45.0 minutes, P=0.001). Conclusions Coronary revascularization guided by iFR was noninferior to revascularization guided by FFR with respect to the risk of major adverse cardiac events at 1 year. The rate of adverse procedural signs and symptoms was lower and the procedural time was shorter with iFR than with FFR. (Funded by Philips Volcano; DEFINE‐FLAIR ClinicalTrials.gov number, NCT02053038.)
Eurointervention | 2015
Emanuele Barbato; Didier Carrié; Petros S. Dardas; Jean Fajadet; Georg Gaul; Michael Haude; Ahmed Khashaba; Karel T. Koch; Markus Meyer-Gessner; Jorge Palazuelos; Krzysztof Reczuch; Flavio Ribichini; Samin K. Sharma; Johann Sipötz; Iwar Sjögren; Gabor Suetsch; György Szabó; Mariano Valdes-Chavarri; Beatriz Vaquerizo; William Wijns; Stephan Windecker; Adam de Belder; Marco Valgimigli; Robert A. Byrne; Antonio Colombo; Carlo Di Mario; Azeem Latib; Christian W. Hamm
The interest in rotational atherectomy (RA) has increased over the past decade as a consequence of more complex and calcified coronary stenoses being attempted with percutaneous coronary interventions. Yet adoption of RA is hampered by several factors: amongst others, by the lack of a standardised protocol. This European expert consensus document stems from the awareness of the large heterogeneity in the protocols adopted to perform rotational atherectomy. The objective of the present document is to provide some points of consensus among highly experienced operators on the most controversial steps of RA in an attempt to build the basis of a standardised and universally accepted protocol.
American Journal of Cardiology | 1996
Mohamed Saleh; Azza El Fiky; Mohsen Fahmy; Nabil Farag; Ahmed Khashaba
Percutaneous balloon mitral commissurotomy with the Inoue technique was attempted in 9 patients with rheumatic mitral stenosis under the sole guidance of biplane transesophageal echocardiography and was completed in 8 patients. This preliminary experience points to the feasibility and relative safety of performing percutaneous balloon mitral commissurotomy under the sole guidance of biplane transesophageal echocardiography.
Clinical Medicine Insights: Cardiology | 2014
Ahmed Khashaba; Ayman Mortada; Azza Omran
Background Maximal hyperemia is the critical prerequisite for fractional flow reserve (FFR) assessment. Despite intravenous (IV) adenosine currently being the recommended approach, intracoronary (IC) administration of adenosine constitutes a valuable alternative in everyday practice. However, it is surprisingly unclear which IC strategy allows the achievement of FFR values that are comparable to IV adenosine. Objectives This study sought to compare increasing doses of IC adenosine versus IV adenosine for FFR. Methods 30 intermediate coronary stenoses undergoing FFR measurement were prospectively and consecutively enrolled. Hyperemia was sequentially induced by bolus of IC adenosine (ADN; 150 μg) followed by IV adenosine (IVADN) infusion over 3 minutes at dose of (140 μg/kg/min). FFR values, symptoms, and development of atrioventricular block were recorded. Results 150 μg doses of IC adenosine were well tolerated and associated with fewer symptoms than IV adenosine. Intracoronary adenosine doses induced a significant decrease of FFR compared with baseline levels (P < 0.01). Among the 6 patients with FFR values less than 0.80 identified by IVADN, 4 were correctly identified also by 150 μg bolus IC adenosine. Larger randomized studies with cross-over design are necessary to verify the results. Conclusions This small pilot study suggests that IC adenosine might be an alternative to IV adenosine. Larger randomized studies with a cross-over design are necessary.
Catheterization and Cardiovascular Interventions | 2008
Mohammad A. Sherif; Ahmed Khashaba; Yaser Gomaa; Saeed Khaled; Osama Refaie; Ali Ramzy
Till now, no pooled analysis summarizing the Egyptian experience in percutaneous mitral valvuloplasty (PMV) exists.
Jacc-cardiovascular Interventions | 2015
Javier Escaned; Mauro Echavarria-Pinto; Hector M. Garcia-Garcia; Tim van der Hoef; Ton de Vries; Prashant Kaul; Ganesh Raveendran; John D. Altman; Howard I. Kurz; Johannes Brechtken; Mark Tulli; Clemens von Birgelen; Ahmed Khashaba; Allen Jeremias; Jim Baucum; Raúl Moreno; Martijn Meuwissen; Gregory Mishkel; Robert-Jan van Geuns; Howard Levite; Ramon Lopez-Palop; Marc Mayhew; Patrick W. Serruys; Habib Samady; Jan J. Piek; Amir Lerman
The Egyptian Heart Journal | 2014
Khaled E. Darahim; Mohsen M. Mahdy; Mona M. Ryan; Ahmed Khashaba; Sameh S. Thabet; Ossama Hassan; Mohammed Amin Abdelhamid
Jacc-cardiovascular Interventions | 2018
Javier Escaned; Nicola Ryan; Hernán Mejía-Rentería; Christopher Cook; Hakim-Moulay Dehbi; Eduardo Alegría-Barrero; Ali Alghamdi; Rasha Al-Lamee; John D. Altman; Alphonse Ambrosia; Sérgio B. Baptista; Maria Bertilsson; Ravinay Bhindi; Mats Birgander; Waldemar Bojara; Salvatore Brugaletta; Christopher E. Buller; Fredrik Calais; Pedro Canas Silva; Jörg Carlsson; Evald H. Christiansen; Mikael Danielewicz; Carlo Di Mario; Joon-Hyung Doh; Andrejs Erglis; David Erlinge; Robert Gerber; Olaf Going; Ingibjörg Gudmundsdottir; Tobias Härle
The Egyptian Heart Journal | 2014
Ahmed Khashaba; Walaa Adel; Alaa Roshdi; Ahmed Gafar; Sherif Essam; Mohammad A.S. Algendy
The Egyptian Journal of Hospital Medicine | 2017
Ahmed Khashaba; Khaled Abdel Azeem Shokry; Yaser Gomaa